Medical Management of Benign Prostatic Hyperplasia - Are Two Drugs Better Than One?

New England Journal of Medicine

Volumn 349, Issue 25, 2003, Pages 2449-2451

  Vaughan Jr , E Darracott ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; AGING; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GENETIC POLYMORPHISM; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; SIDE EFFECT; SRD5A2 GENE; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0347381169     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe038154     Document Type: Editorial

References (17)

1. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75-9.
2. Mebust WK, Holtgrewe LH, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141;243-7.
3. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.
4. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
5. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
6. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975;47:193-202.
7. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158; 481-7.
8. Gormley GJ, Stoner E, Bruskewitz KC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327:1185-91.
9. McConnell JD, Bruskewitz MD, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.
10. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-9.
11. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.
12. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163:13-20.
13. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
14. Ware JH. The National Emphysema Treatment Trial - how strong is the evidence? N Engl J Med 2003;348:2055-6.
15. Civantos F, Watson RB, Pinto FE, et al. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997;6;1-13.
16. Makridakis NM, di Salle E, Reichardt JKV. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000;10:407-13.
17. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134-9.